Apimeds Pharmaceuticals US Inc（APUS）の株式分析APUSApimeds Pharmaceuticals US Inc

Apimeds Pharmaceuticals US, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in developing Apitox, an intradermally administered bee venom-based toxin. It is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions. It operates in the Healthcare sector.

Given the current price of 3.87, the RSI of 30.157 indicates that the stock is oversold, but the significant year-to-date change of -97.68% and negative net income figures suggest that the company is struggling financially. The recent leadership changes and settlement agreements may provide some hope for recovery, but the risks are substantial, particularly with a projected trajectory indicating a potential future change of +243.47% based on historical patterns, which is speculative at best. The main risk is the company's current liabilities exceeding its assets, leading to a current ratio of 0.00.